Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Accumulated Expenses (2016 - 2025)

Amicus Therapeutics filings provide 14 years of Accumulated Expenses readings, the most recent being $200.5 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 57.47% to $200.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $200.5 million, a 57.47% increase, with the full-year FY2025 number at $200.5 million, up 57.47% from a year prior.
  • Accumulated Expenses hit $200.5 million in Q4 2025 for Amicus Therapeutics, up from $171.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $200.5 million in Q4 2025 to a low of $57.2 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $125.1 million (2022), compared with a mean of $118.8 million.
  • Biggest five-year swings in Accumulated Expenses: dropped 19.13% in 2021 and later soared 72.85% in 2022.
  • Amicus Therapeutics' Accumulated Expenses stood at $98.2 million in 2021, then dropped by 4.6% to $93.6 million in 2022, then surged by 54.05% to $144.2 million in 2023, then decreased by 11.75% to $127.3 million in 2024, then skyrocketed by 57.47% to $200.5 million in 2025.
  • The last three reported values for Accumulated Expenses were $200.5 million (Q4 2025), $171.2 million (Q3 2025), and $145.1 million (Q2 2025) per Business Quant data.